Inducing ICD with NPs is a viable therapeutic strategy to potentiate anti-tumor immunity. The convergence of NPs-based ICD inducers with nanotechnology-based delivery systems offers a robust platform for the development of innovative combination regimens aimed at improving patient outcomes.
Chen et al. (Tue,) studied this question.